Even with the coronavirus pandemic ravaging Europe and much of the world, patient advocate Lucia Monaco, PhD, of Italy remains confident that the Paris-based nonprofit she chairs will see the approval of 1,000 new rare disease therapies by 2027. That group, the International Rare Diseases Research Consortium (IRDiRC) —…
Just Published
Long-term treatment with the investigational oral therapy soticlestat (OV935/TAK-935) can reduce the median seizure frequency by up to 90% in adults with Lennox-Gastaut syndrome (LGS) and other developmental and epileptic encephalopathies (DEE), according to data from the ENDYMION Phase 2 trial. Topline results are expected in the…
Recent Posts
- Clinical trial data back benefits of LGS seizure med, analysis finds
- EEG headband tracks LGS kids’ sleep disturbances at home
- Making the best of vacationing while caring for a child with LGS
- Combined nerve stimulation linked to greater seizure reductions in LGS
- Navigating my son’s constantly changing eating habits can be tricky